In vivo characterisation of the chemokine recep-tor CXCR4 to detect an inflammation in athero-sclerotic plaques by means of PET/MR

Funded period

2017 – 2017

Granted budget

€ 28,140



Therapeutic Principle


Principal Investigator

Markus Schwaiger (Klinikum rechts der Isar der Technischen Universität München)

It was demonstrated in preliminary studies with animal atherosclerosis models that the radionuclide 68Ga-Pentixafor binds specifically to cells which mediate an inflammation process and thus enables a non-invasive assessment of an inflammation in atherosclerotic plaques.

This project shall carry out the necessary toxicity and dose tests for an initial application in humans. If these tests are successfully completed, the proof of concept shall be demonstrated in patients, whereby it shall be determined whether the incorporated amount of 68Ga-Pentixafor correlates with the expression of CXCR4